Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2003

View Archived Issues

Activation of LXRs prevents development of atherosclerosis

Label extension approved for Cozaar

Emend approved by FDA for chemotherapy-induced nausea and vomiting

Novel tyrosine kinase inhibitors and their use reported by Merck

Florida State researchers prepare new antitumor paclitaxel derivatives

New antimalarial compounds designed by Japanese scientists

BMS researchers describe new inhibitors of MMPs, TACE and/or aggrecanase

Pfizer designs new PDE4 inhibitors

Lion Bioscience presents novel FXR modulators for lipid disorders and cancer

New monoamine receptor modulators covered by Sepracor patent

Novel antagonists of non-CB1/CB2 cannabinoid receptors with utility in septic shock

Merck identifies novel alpha2/alpha3-selective GABA-A receptor modulators

Vicuron and Novartis extend collaboration

InSite advances therapeutic programs

Titan focuses on four key programs

Telik initiates phase III ASSIST-1 trial of TLK-286 in ovarian cancer

Two HIV vaccine candidates used in combination show promise in monkeys

Completion of rasagiline phase III program

DCF-987 phase II trial on track

BioXell commences phase II trial of BXL-628

Abbott and Karo Bio identify novel new compound for type 2 diabetes

NaPro BioTherapeutics licenses peptide targeting technology from M.D. Anderson

Alfimeprase safe and well tolerated in phase I

Tumor suppressor gene polypeptides, compositions and methods of use available from NIH

NIH offers for licensing invention for optimizing cardiac contraction

Potent, orally active Lp-PLA2 inhibitor in clinical development for atherosclerosis

New revised guidelines on tuberculosis issued by the ATS, the U.S. CDC and the IDSA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...